Psoriatic Arthritis Market is estimated to be 14.8 Billion by 2029 with a CAGR of 9.0% during the forecasted period.

 

Psoriatic Arthritis is a form of arthritis that affects some people who have psoriasis — a condition that features red patches of skin topped with silvery scales. Most people develop psoriasis first and are later diagnosed with psoriatic arthritis, but the joint problems can sometimes begin before skin patches appear. Psoriatic arthritis can affect joints on just one side or on both sides of your body and cause joints to become painful, swollen and warm to the touch. The global mice model market accounted for US$ 6.9 billion in 2020 and is estimated to be US$ 14.8 billion by 2029 and is anticipated to register a CAGR of 9.0%.

The report "Global Psoriatic Arthritis Market, By Drug Class (DMARD, NSAIDs, Biologics, and Others), By Product Type (OTC and Prescriptions), By Route of Administration (Oral, Topical, and Injectable), and By Region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa) - Trends, Analysis and Forecast till 2029”.

Key Highlights:

·         In October, 2020, The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended approval for the expanded use of guselkumab (Tremfya), a monoclonal antibody (mAb) from the Janssen Pharmaceutical Companies of Johnson & Johnson. 

·         In in October 2020, British Association of Dermatologists updated Clinical practice guidelines for biologic therapy for psoriasis.

Analyst View:

Psoriatic arthritis cases are increasing every year. According to a publication by the International Journal of Clinical Rheumatology, psoriatic Arthritis is considered part of the spondylarthritis group, which is present in up to 42% of individuals with psoriasis and up to 15% of patients with psoriasis may have undiagnosed psoriatic arthritis. With the increasing cases there is an increase in the drugs and the diagnosis thereby boosting the psoriatic arthritis market.

Over the past few years there has been an advancement in the development of personalized drug development. This unable to target the exact location, tissue, or the region that needs to be treated. For instance, Otezla is a new drug that has been approved in 2014 for psoriatic arthritis. This drug is an oral phosphodieasterase-4 (PDE-4) inhibitor that will decreases proinflammatory mediators and increases anti-inflammatory mediators.

Key Market Insights from the report:        

The global psoriatic arthritis market accounted for US$ 6.9 billion in 2020 and is estimated to be US$ 14.8 billion by 2029 and is anticipated to register a CAGR of 9.0%. The market report has been segmented on the basis of drug class, product type, route of administration and region.

·         Depending upon drug class, DMARDs are projected to dominate the market due to their first-line of treatment, demand, and applicability of corticosteroids, and the forthcoming launches of key pipeline products, such as upadacitinib, filgotinib, and BMS-986165.

·         Depending upon the product type, the Prescription segment is projected to register highest share of the market and are likely to maintain the lead throughout the forecast period. As most biologics and DMARDs are sold as prescriptions.

·         In terms of route of administration, Injectables led the global psoriatic arthritis market, due to the anticipated launches of biologics and biosimilars. Most biologics are injected through the subcutaneous or intravenous routes.

·         By region, North America and Europe, collectively dominates the global psoriatic arthritis market mainly due to the commercial sales of products in the U.S. In addition, the presence of key manufacturers, proactive government initiatives, favorable reimbursement policies, and a large patient pool support the psoriatic arthritis treatment market growth. Further the market is expected to grow the fastest in the regions of Asia Pacific due to the overall economic development, improvement in healthcare infrastructure, increase in disposable income, and rise in consumer awareness.

Before purchasing this report, request a sample or make an inquiry by clicking the following link:

https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/4520

Competitive Landscape:

The prominent player operating in the global psoriatic arthritis market includes AbbVie Inc., Amgen Inc., Johnson & Johnson Services, Inc., AstraZeneca plc; Bausch Health Companies Inc., Bristol-Myers Squibb Company, Celgene Corporation, Novartis International AG, Eli Lilly and Company, Pfizer, Inc. and UCB S.A. Strategic..

The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.

About Prophecy Market Insights

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

To know more

Contact Us:

Sales

+1 860 531 2701

Email- sales@prophecymarketinsights.com

 

Comments

Post a Comment

Popular posts from this blog

Monkeypox Disease Diagnostics Market - The abrupt global expansion of the monkeypox virus has increased the demand for monkeypox diagnostics.

Image
  The virus that causes smallpox and the Monkeypox both belong to the same family of viruses. Two outbreaks of a disease resembling the pox in groups of monkeys used for study led to the discovery of monkeypox in 1958. However, it has been observed in various parts of the world except Africa, where it is primarily found. It results in symptoms that resemble the flu, such as fever, chills, and a rash that might take weeks to go away. Even though instances of monkeypox are uncommon, they are growing in Africa and other areas where they have never before occurred. The fact that monkeypox is a rare disease may lead a healthcare provider to first rule out other rash infections, such measles or chickenpox. A tissue sample from an open sore is the first step in the medical professional's diagnosis of monkeypox (lesion). After that, send to a lab for PCR (Polymerase Chain Reaction). Additionally, blood is drawn to test for antibodies or the monkeypox virus. Currently, there is no licens
Read more

Humanized Liver Mice Model Market is estimated to be US$ 133.72 billion by 2030 with a CAGR of 5.30% during the forecast period

Image
Humanized Liver Mice Model Market   accounted for US$ 78.64 million in 2020 and is estimated to be US$ 133.72 million by 2030 and is anticipated to register a CAGR of 5.30%.  A lot of studies are underway to create novel humanized liver mouse models. Initially, liver mice models were created by implanting human liver cells or hepatic cancer cells into basic immune-deficient mice. The results, however, were inconsistent and unreliable. As a result, immune-deficient mice were developed, which spontaneously destroy the mice liver, allowing human liver cells to proliferate and replace it, resulting in stable humanized liver mice models. For example, a number of research projects are looking into using PPARalfa and AFC8-based mice models to develop humanized liver mice models. The report "Global Humanized Liver Mice Model Market, By Model (uPA-SCID, FRG KO Mice, TK-NOG Mice  and Other Models) By Application (Pharmacokinetics Studies, In-vivo Liver Toxicity Testing, Drug Metabolism Stud
Read more

Bipolar Disorder Market is estimated to be US$ 6.7 billion by 2030 with a CAGR of 2.3% during the forecast period

Image
Bipolar Disorder Market   accounted for US$ 5.3 billion in 2020 and is estimated to be US$ 6.7 billion by 2030 and is anticipated to register a CAGR of 2.3%. Bipolar disorder known as manic depression is a mental illness that brings low moods and severe high moods, thinking, changes in sleep and have periods in which they feel overly happy and energized and other side feel very sad, hopeless and sluggish. Bipolar disorder can cause severe disruption to a person’s life which can be treated with appropriate treatment and support. The report "   Global Bipolar Disorder Market, By Disorder (Bipolar I Disorder, Bipolar II Disorder, Cyclothymic Disorder), By Drug Class (Mood Stabilizer, Anticonvulsant, Antipsychotic Drugs, Antidepressant Drugs, and Antianxiety Drugs), By Mechanism of Action (Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Tricyclic Antidepressants, Beta Blockers, and Benzodiazepines), By Region (North
Read more